Sign Up

Sign up to our social GMP Questions and Answers Engine to ask and answer questions, and connect with other professionals.

Have an account? Sign In
or use


Have an account? Sign In Now

Sign In

Login to our social GMP Questions and Answers Engine to ask and answer questions and connect with other professionals.

Sign Up Here
or use

Forgot Password?

Don't have account, Sign Up Here

Forgot Password

Lost your password? Please enter your email address. You will receive a link and will create a new password via email.


Have an account? Sign In Now
You must login to ask question.

or use

Forgot Password?

Need An Account, Sign Up Here
Qualistery – GMP Knowledge Provider Logo Qualistery – GMP Knowledge Provider Logo
Sign InSign Up

Qualistery – GMP Knowledge Provider

Qualistery – GMP Knowledge Provider Navigation

  • Home
  • GMP Learning
    • Live GMP Webinars
    • Webinar Recordings
  • Resources
    • Articles
    • Podcast
  • Speaking & Sponsorship
    • Speaking Partners (Organization)
    • Event Sponsorship
    • Speaking and Training Opportunities For GxP Experts
  • Contact
  • My Account
Search
Ask A Question

Mobile menu

Close
Ask a Question
  • Home
  • GMP Learning
    • Live GMP Webinars
    • Webinar Recordings
  • Resources
    • Articles
    • Podcast
  • Speaking & Sponsorship
    • Speaking Partners (Organization)
    • Event Sponsorship
    • Speaking and Training Opportunities For GxP Experts
  • Contact
  • My Account
Home/ Questions/Q 779
In Process
Adv
Anonymous
  • 0
Anonymous
Asked: August 20, 20212021-08-20T16:05:37+02:00 2021-08-20T16:05:37+02:00In: Management

What should drug manufacturers do to prevent formation of glass lamellae (glass fragments) in injectable drugs filled in small-volume glass vials?

  • 0

What should drug manufacturers do to prevent the formation of glass lamellae (glass fragments) in injectable drugs filled in small-volume glass vials?

glasslamellaemanufacturers
  • 1 1 Answer
  • 158 Views
  • 0 Followers
  • 0
Answer
Share
  • Facebook
    Adv

    1 Answer

    • Voted
    • Oldest
    • Recent
    • Random
    1. Qualistery Level 2
      2021-09-03T14:08:23+02:00Added an answer on September 3, 2021 at 2:08 pm

      Under certain conditions, glass vials can shed thin, flexible fragments called glass lamellae (Lachman, Lieberman, et al. 1986; Iacocca, Toltl, et al. 2010).

      These lamellae are shed from the interior surface of the glass container directly into the drug and are difficult to detect by visual inspection. Several drugs have been recalled due to this problem: epoetin alfa, methotrexate, hyaluronidase recombinant, and fluorouracil (see Enforcement Reports on FDA’s Web Site).

      No adverse events to date have been reported, nor can they be directly attributed to this phenomenon. However, there is the potential for drugs administered intravenously that contain these fragments to cause embolic, thrombotic, and other vascular events (e.g., phlebitis); and, when administered subcutaneously, to lead to the development of foreign body granuloma, local injection site reactions, and increased immunogenicity (Singh, Afonina, et al. 2010).

      The following conditions have been associated with a higher incidence of the formation of glass lamellae: Glass vials manufactured by a tubing process (and thus manufactured under higher heat). These vials are less resistant than moulded glass vials and may shed lamellae more easily (Ennis, Pritchard, et al. 2001).

      The processing conditions used to manufacture glass vials can be designed to mitigate the potential for later delamination. Drug solutions formulated at high pH (alkaline) and with certain buffers. Common buffers associated with lamellae formation include citrate and tartrate (Sacha, et al., 2010).

      Length of time the drug product is exposed to the inner surface of the container. The time duration directly correlates to the potential for glass lamellae formation to occur during the product shelf life (Lachman, Lieberman, et al. 1986).

      Drug products with room temperature storage requirements. Drugs stored at room temperature have a greater chance of glass lamellae formation than products stored at colder temperatures (Iacocca and Allgeier 2007). Terminal sterilization significantly affects glass stability (Iacocca, Toltl, et al., 2010). The referenced literature below includes recommended actions to help prevent the formation of glass lamellae. For example, for products “at risk,” the vial surface alkalinity can be minimized by proper selection of glass composition (e.g., highly resistant, non-alkaline earth borosilicate glass), appropriate selection and qualification of vendors, and proper quality control of the incoming vials.

      Accordingly, FDA advises drug manufacturers of products to reexamine their supplier quality management program with the glass vial manufacturers to ensure that this phenomenon is not occurring. Further, the Agency reminds finished drug product manufacturers that CGMP regulations require that drug containers not be reactive or additive to alter the safety or quality of the drug. See 21 CFR 211.94; Rx-360’s Web site external Link Disclaimerdisclaimer icon, which has commented on the issue of delamination; and deviation reporting regulations for field alert reports (21 CFR 314.81) and biological product deviation reports (21 CFR 600.14).

      References: Lachman, L, H Lieberman, and J Kanig, 1986, The Theory and Practice of Industrial Pharmacy, 3rd ed., Philadelphia: Lippincott Williams & Wilkins, 645–649, 796–798 Iacocca, RG, N Toltl, et al., 2010, Factors Affecting the Chemical Durability of Glass Used in the Pharmaceutical Industry, AAPS Pharm Sci Tech, DOI:10.1208/s12249-010-9506-9 Singh SK, N Afonina, et al., 2010, An Industry Perspective on the Monitoring of Subvisible Particles as a Quality Attribute for Protein Therapeutics, J Pharm Sci, 99(8):3302–3321 Ennis RD, R Pritchard, et al., 2001, Glass Vials for Small Volume Parenterals: Influence of Drug and Manufacturing Process on Glass Delamination, Pharm Dev and Tech, 6(3):393–405 Sacha, G., et al., 2010, Practical Fundamentals of Glass, Rubber, and Plastic Sterile Packaging Systems, Pharm Dev and Tech, 15(1):6–34 Iacocca, RG, and M Allgeier, 2007, Corrosive Attack of Glass by a Pharmaceutical Compound, J Mater Sci, 42:801–811 21 CFR 211.94: Drug product containers and closures 21 CFR 314.81: Other postmarketing reports 21 CFR 600.14: Reporting of biological product deviations by licensed manufacturers

      • 1
      • Reply
      • Share
        Share
        • Share on Facebook
        • Share on Twitter
        • Share on LinkedIn
        • Share on WhatsApp

    Leave an answer
    Cancel reply

    You must login to add an answer.

    or use

    Forgot Password?

    Need An Account, Sign Up Here
    Adv

    Sidebar

    Ask A Question

    Stats

    • Questions 103
    • Answers 117
    • Best Answer 1
    • Users 71
    • Popular
    • Answers
    • Anonymous

      tablet hardness

      • 5 Answers
    • Qualistery

      What is Data Governance?

      • 3 Answers
    • Qualistery

      What is data life cycle?

      • 2 Answers
    • Md.Mahamudul Hossain Robin
      Md.Mahamudul Hossain Robin added an answer It is Completely depends on the design . There is… December 7, 2022 at 4:53 am
    • Yan Kugel
      Yan Kugel added an answer Dear Nadia, a recall is an action which the manufacturer… October 8, 2021 at 5:20 pm
    • Marc García Gómez
      Marc García Gómez added an answer Pharmaceutical manufacturers must demonstrate that bacterial, fungal, and yeast contamination… October 3, 2021 at 12:31 pm

    Top Members

    Yan Kugel

    Yan Kugel

    • 0 Questions
    • 88 Points
    Level 2
    Qualistery

    Qualistery

    • 85 Questions
    • 78 Points
    Level 2
    Shashi Ravi Suman Rudrangi, RPh

    Shashi Ravi Suman Rudrangi, RPh

    • 0 Questions
    • 33 Points
    Level 1

    Trending Tags

    Active Pharmaceutical Ingredient Airlock ALCOA+ analytical api APIs archiving A true copy audit trail Authorized Person Batch Batch Records Batch Recovery batch reworking Bracketing Calibration capa CGMP Change Control Clean Area cleaning cold chain monitoring Confirmation Testing Consignment contact lens solution Contamination Control Strategy Corrective Action Cross Contamination Data Governance data life cycle Delivery Design Space document retention schedule Drug Master File effectiveness electronic signature finished Pharmaceutical Product flexible intravenous glass GMP gmp&iso 9001 Good Manufacturing Practices good practices (GxP) hbel HBELs healthbased exposure limit health based exposure limit in-process control (IPC) In Process Control InterCompany Transfer Intermediate Product lamellae Large Volume Parenterals manufacturers manufacturing Marketing Authorization medical device medicinal metadata Operational Qualification Packaging Packaging Material pathogenic Performance Qualification Pharmaceutical manufacturers Pharmaceutical Manufacturing Pharmaceutical Product Pharmaceutical Production Pharmacopeia pq PQR process validation Product products QA QC Qualification Quality Assurance Quality Control Quality Planning quality policy quality risk management (QRM) Quality Unit Quarantine question raw material Reconciliation Reprocessing Sampling Self Contained Area single product solution bags sop special Specification Standard Operating Procedure starting material supplier qualifications supplier quality suppliers technology transfer usp Validation validation batches Validation batches in a Technology transfer Validation Master Plan validation report vp vr

    Explore

    • Home
    • Add group
    • Groups page
    • Communities
    • Questions
      • New Questions
      • Trending Questions
      • Must read Questions
      • Hot Questions
    • Polls
    • Tags
    • Badges

    Footer

    Qualistery - GMP Knowledge Provider

    Qualistery is a GMP knowledge database, and a social Questions & Answers engine which will help you dominate the arena.

    Company

    • About Us
    • Contact Us

    Legal

    • Impressum – Legal Disclosure
    • Privacy Policy
    • Cookie Policy
    • Terms and Conditions
    • Disclaimer

    Services

    • GMP Online Education

    GMP Resources

    • Articles
    • Podcast

    Follow

    © 2022 Qualistery. All Rights Reserved

    Insert/edit link

    Enter the destination URL

    Or link to existing content

      No search term specified. Showing recent items. Search or use up and down arrow keys to select an item.